Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide

Nephrology

Volumn 23, Issue 9, 2018, Pages 883-886

  Takada, Tesshu ^a   Masaki, Tsuguto ^a   Hoshiyama, Ayako ^a   Toki, Takuya ^a   Kamata, Yuji ^a   Shichiri, Masayoshi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

diabetic renal failure; diuretics; fluid retention; heart failure; nephrotic syndrome; tolvaptan

Indexed keywords

FUROSEMIDE; TOLVAPTAN; BENZAZEPINE DERIVATIVE; LOOP DIURETIC AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DIURESIS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FLUID RETENTION; FREE WATER CLEARANCE; HEART FUNCTION; HUMAN; HYPERVOLEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; URINE VOLUME; DRUG EFFECT; DRUG RESISTANCE; ELECTROLYTE BALANCE; HEART FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; DIABETIC NEPHROPATHIES; DRUG RESISTANCE; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 85051868373     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.13390     Document Type: Article

References (20)

1. Chida S, Fujita Y, Ogawa A et al. Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: Historical cohort study. Sci. Rep. 2016; 6: 26380
2. Mogensen CE. Management of early nephropathy in diabetic patients. Annu. Rev. Med. 1995; 46: 79–93
3. Akmal M. Hemodialysis in diabetic patients. Am. J. Kidney Dis. 2001; 38: S195–9
4. Kikkawa R, Arimura T, Haneda M et al. Current status of type 2 (non-insulin-dependent) diabetic subjects on dialysis therapy in Japan. Diabetologia 1993; 36: 1105–8
5. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132–43
6. Butler J, Forman DE, Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J. 2004; 147: 331–8
7. Hommel E, Mathiesen ER, Aukland K, Parving HH. Pathophysiological aspects of edema formation in diabetic nephropathy. Kidney Int. 1990; 38: 1187–92
8. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am. J. Cardiol. 2006; 97: 1759–64
9. Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 1998; 287: 860–7
10. Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 2006; 290: F273–8
11. Pang PS, Gheorghiade M, Dihu J et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am. Heart J. 2011; 161: 1067–72
12. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ. J. 2014; 78: 844–52
13. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 2003; 107: 2690–6
14. Gheorghiade M, Konstam MA, Burnett JC Jr et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332–43
15. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291: 1963–71
16. Uemura Y, Shibata R, Takemoto K et al. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 2016; 31: 1643–9
17. Sato E, Nakamura T, Amaha M et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int. Heart J. 2014; 55: 533–8
18. Kida K, Shibagaki Y, Tominaga N et al. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: A pharmacokinetic and pharmacodynamic study. Clin. Pharmacokinet. 2015; 54: 273–84
19. Imamura T, Kinugawa K, Shiga T et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients-association between non-responders and chronic kidney disease. Circ. J. 2013; 77: 397–404
20. Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014; 85: 953–61